Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

2023-508756-19-00 Protocol IRST100.39 Human pharmacology (Phase I) - Other Ended

Start 29 Oct 2019 · End 24 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol IRST100.39

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 18
Countries 1
Sites 1

Mesothelioma

Key facts

Sponsor
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
29 Oct 2019 → 24 Oct 2025
Decision date (initial)
2024-08-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-508756-19-00
EudraCT number
2018-000500-42
ClinicalTrials.gov
NCT03546426

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Mesothelioma

VersionLevelCodeTermSystem organ class
20.0 PT 10027406 Mesothelioma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Sponsor organisation
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Address
Via Piero Maroncelli 40
City
Meldola
Postcode
47014
Country
Italy

Scientific contact point

Organisation
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Contact name
Laura Ridolfi

Public contact point

Organisation
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Contact name
Oriana Nanni

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 18 1
Rest of world 0

Investigational sites

Italy

1 site · Ended
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Experimental and Clinical Oncology of Immunotherapy and Rare Cancers Unit, Via Piero Maroncelli 40, 47014, Meldola

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2019-10-29 2019-10-30 2024-09-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-10 Italy Acceptable
2024-07-24
2024-08-05
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-22 Italy Acceptable
2025-10-13
2025-10-14